Stockreport

Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development [Yahoo! Finance]

Altimmune, Inc.  (ALT) 
NASDAQ:AMEX Investor Relations: altimmune.com/investors
PDF TheFly reported on January 27 that Barclays initiated coverage of ALT with an Overweight rating and a $20 price target. Strong underlying fundamentals, continuous merge [Read more]